In listening to the lecture Dr. Mikovits gave in Sweden, I understood her to be describing the attributes of the LNCaP cell line that led her to select it, not so much the LTR response. Her "guess" as to what cell line (LNCaP) to use as based, in part, on it's androgenic response but I can't recall why that was a criterion for a cell line so perhaps it's just my fuzzy memory. She was a bit modest in calling it a "guess". Darn good educated guess, I'd say. Too bad it won't grow the "poly" variants Lo/Alter found.